Genmab Stock (GMAB) Soars Over 30% on Strong Phase 3 Results for the Company’s Head and Neck Cancer Treatment
Genmab stock saw an over 30% rally on Wednesday following a clinical trial update for its head and neck cancer drug.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Darwin Global Management Abhishek Trehan | 17,899,876 | $638,578,076 | 16% | |
| 2. | Paradigm Biocapital Advisors Senai Asefaw | 14,136,472 | $504,318,639 | +8% | 10.03% |
| 3. | Orbis Investment Management William B. Gray | 10,567,391 | $376,991,674 | -8% | 1.25% |
| 4. | Deerfield Management James E. Flynn | 6,865,000 | $244,908,875 | 3.79% | |
| 5. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 6,069,276 | $216,521,421 | +22% | 0.09% |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 6,403,228 | $228,434,799 | 0.07% | |
| 2. | 6,057,192 | $216,090,316 | 0% | |
| 3. | 4,349,551 | $155,170,232 | 6.74% | |
| 4. | 3,900,744 | $139,159,050 | 0.02% | |
| 5. | 2,902,410 | $134,231,431 | 1.48% |